A new osteoporosis guideline by the Endocrine Society puts a premium on women at high risk of fractures, particularly those who have had a recent fracture after menopause, and outlines the latest pharmacologic options for specific patient groups.
Walking downhill within 1 hour after meals may help reduce bone resorption in postmenopausal women with diabetes, according to new research. Walking uphill does not provide the same osteogenic response.
A contraceptive vaginal system (Annovera) releasing a combination of segesterone acetate and ethinyl estradiol (SA/EE) effectively inhibits ovulation up to a year even at low systemic levels of SA, reports a review study presented at ENDO 2019.
Individuals with poorly controlled type 2 diabetes (T2D) had greater HbA1c reductions and weight loss when a 7 or 14 mg/day dose of the GLP-1* receptor agonist semaglutide rather than sitagliptin was added to their background diabetic medications, results of the phase IIIa PIONEER 3** trial showed.
Treatment with the oral 11β-hydroxylase inhibitor osilodrostat continues to maintain a normalized mean urinary free cortisol (mUFC) in patients with Cushing’s Disease (CD) in a phase III trial presented at ENDO 2019.
Long-term testosterone therapy in obese men with hypogonadism led to sustained weight loss and improvements in multiple anthropometric parameters, according to an observational study presented at ENDO 2019.
The novel androgen 11-beta-methyl-19-nortestosterone dodecylcarbonate (11β-MNTDC) – a modified testosterone with androgenic and progestational activity being developed as a male contraceptive – effectively suppressed endogenous gonadotropin and testosterone production in healthy men, consequently preventing pregnancies, according to data presented at ENDO 2019.
Ovarian function in transgender men remained well-preserved even after a year of testosterone treatment, providing hope for trans men who would like to bear children in the future, according to data presented at ENDO 2019.
Sperm appears to play a role in repeat miscarriages, as elevated levels of semen reactive oxygen species (ROS), elevated sperm DNA fragmentation, and a lower percentage of normal morphology were found in male partners of women with idiopathic recurrent pregnancy loss* (RPL), according to data presented at ENDO 2019.
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.